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Martina Calore, PHD, Leon J. De Windt, PHDI t is not hard to imagine why in Greek mythologyliterally dozens of deities existed that repre-sented the Earth’s rivers and streams. Okea-
nides, the goddesses of streams, and Naiades, the
nymphs of freshwater springs, were all related to
the Potamoi, the gods of the rivers and streams of
the earth and the powerful earth-encircling river
Okeanos. In Greek antiquity, it was clear that in a
dry and hot Mediterranean climate, the city-states
critically depended on the Naiades and their supply
of freshwater to convert barren lands into thriving
oases. In fact, the Greek embraced the abundant
sources of freshwater and the neighboring seas as
signs of blessings, as their absence would inevitably
mean drought, hunger, suffering, disease, inability
to trade and, ﬁnally, political instability, war, and
death.
The complex events in cardiac remodeling consist
of varying degrees of myocyte hypertrophy and
death, interstitial ﬁbrosis, and dysfunctional blood
vessel formation resulting in deﬁcient oxygen supply
(1) and may well bear analogy to the antique Greek
lands and mythological Naiades. Angiogenesis, the
sprouting of new blood vessels from pre-existing
vasculature, represents an important adaptive
mechanism of the myocardium to ischemia or to
conditions of sustained increased demand. After
myocardial infarction, rapid formation of collateral
vessels bypassing the obstructed coronary artery is*Editorials published in the Journal of the American College of Cardiology
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the infarcted region. Therapeutic angiogenesis as an
intervention strategy to revascularize the ischemic
tissue has been pursued in pre-clinical studies in
post–myocardial infarction animal models as well as
in clinical studies of patients by delivering various
angiogenic growth factors (2). Yet therapeutic angio-
genesis has the potential to beneﬁt even more
patients with heart failure (HF). Pressure overload,
induced by hypertension or aortic stenosis, is
accompanied by increased coronary resistance,
impaired myocardial vascularization, and adverse
changes in the extracellular matrix composition
causing enhanced myocardial oxygen demand that
could be overcome by neovascularization (3). Despite
the theoretical beneﬁt of neoangiogenesis for various
subtypes of HF, the endogenous factors controlling
myocardial neovascularization remain limited to
a subset of growth factors with varying clinical
beneﬁt (4). Because available HF pharmacotherapy
has only a marginal impact on long-term prognosis of
the disease, there is both space and need to develop
new biotherapeutics to improve the myocardial
vasculature.LONG NONCODING RIBONUCLEIC ACIDS AS
ENDOGENOUS “GENES” CONTROLLING
ANGIOGENESIS
The results of the Encyclopedia of DNA Elements and
the Functional Annotation of Mouse consortia have
considerably changed the understanding of our
genome by reporting that at least 80% of the genome
is transcribed and functional, whereas <3% has
protein-coding potential. Increasing evidence in-
dicates that noncoding deoxyribonucleic acid (DNA)
are hardly “junk” DNA but functionally active as
ribonucleic acid (RNA) molecules. Noncoding RNAs
can be classiﬁed according to their length into small
noncoding RNAs (<200 nucleotides), including
microRNAs (miRs), transfer RNAs, and small nucleolar
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2017RNAs, or long noncoding RNAs (lncRNAs) (>200 nu-
cleotides), comprising ribosomal RNAs, natural anti-
sense transcripts, and others. Although humans have
about 25,000 genes, the numbers of miRs and
lncRNAs have been estimated to be about 2,500 and
about 50,000, respectively, thus practically tripling
the number of candidate “genes” potentially involved
in (patho)physiological processes such as myocardial
angiogenesis.
LncRNAs show tissue- and cell type–speciﬁc
expression and different molecular functions, derived
from their ability to act as scaffolds for protein-
protein interactions, transcriptional activators or re-
pressors, and molecular decoys, or serve as central
platforms for assembly of complex protein compo-
nents. Earlier experimental and genetic studies have
already pointed to the possible involvement of
lncRNAs in vascular function and disease, such as
metastasis associated in lung adenocarcinoma tran-
script (MALAT1), maternally expressed 3 (MEG3),
taurine upregulated gene 1 (TUG1), and many addi-
tional unknown lncRNAs (5–9).SEE PAGE 2005In this issue of the Journal, a landmark study by
Fiedler et al. (10) now adds valuable information
by discovering lncRNAs that potentially achieve
therapeutic neovascularization in HF. Fiedler et al.
(10) used an unbiased approach to systematically
screen for hypoxia-responsive human lncRNAs by
next-generation RNA sequencing and microarray
platforms. The investigators discovered no fewer
than 8,000 dysregulated lncRNAs and, for practical
reasons, concentrated on the previously unde-
scribed LINC00323 and MIR503GH, both of which
displayed enrichment in highly vascularized organs
and showed strong hypoxia-mediated induction of
expression.
Silencing LINC00323 transcript variant 3, encoded
on chromosome 21, with short interfering RNA or
GapmeRs, potent antisense oligonucleotides used for
lncRNA function inhibition, led to reduced endothe-
lial proliferation, migration, and tube formation.
Mechanistically, biochemical assays indicated a direct
interaction of LINC00323 with translation initiation
factor eIF4A3 and enrichment of the angiogenic tran-
scription factor GATA2, suggesting that LINC00323
functions as a scaffolding lncRNA that controls
translation of key regulators of endothelial cell (EC)
function. The other candidate lncRNA, MIR503HG,
embedded in chromosome X, possesses a distinct
molecular function. By virtue of identical increases
of miR-503, mapped in the locus of MIR503HG, the
investigators concluded that lncRNA MIR503HGinduces miR-503 expression in a hypoxia-dependent
fashion. Moreover, MIR503HG silencing resulted in
reciprocal induction of the neighboring miR-424,
supporting a cis-action for MIR503HG on miR-424.
Mechanistically, miR-503 and MIR503HG controlled
EC viability and proliferation by altering expression
of the cell-cycle inhibitor p21 and transcription factor
GATA2.
Rather than testing the angiogenic properties of
LINC00323 and MIR503HG in an animal model, the
investigators took this study another innovative step
forward. Because of cardiac internal location in the
body and very low regenerative capacity, intact hu-
man hearts, biopsy samples, and even single cells are
hard to study for cardiovascular biomedical purposes.
These limitations, together with the complete lack of
human cardiac cell lines, have forced reliance on
animal models of cardiovascular diseases, with con-
stant uncertainty about their predictive power and
relative shortcomings to translate pre-clinical efﬁ-
cacy of candidate molecules or therapies into clinical
activity. To overcome these limitations, Eschenha-
gen’s group developed 3-dimensional engineered
heart tissue (EHT) derived from human induced
pluripotent stem cells as a fundamentally new
in vitro humanized disease model exhibiting the
intact heart’s tissue-like arrangement of human car-
diomyocytes (11). In contrast to 2-dimensional cell
cultures, EHTs contain all cardiac cell types, some of
which may potentially model patient-speciﬁc heart
diseases amenable to genetic and pharmacological
studies.
Accordingly, to translate the ﬁndings on LINC00323
and MIR503HG in 3-dimensional vascularized hu-
manized myocardium, the investigators generated
human induced pluripotent stem cells–derived EHTs
enriched with green ﬂuorescent protein–tagged
human ECs for easier identiﬁcation of capillary
abnormalities in the myocardial “organoids” (12).
EHTs transfected with either short interfering RNA to
silence LINC00323 or a GapmeR to repress MIR503HG
demonstrated substantially reduced numbers of ECs
and capillary formation compared with control
transfected EHTs, indicating that also in this model,
LINC00323 and MIR503HG show protective properties
for myocardial EC function.
FUTURE PERSPECTIVES
The data of Fiedler et al. (10) not only support the
contention that relevant regulatory information is
present in the noncoding part of our genome but also
stimulate new biomedical horizons. First, the inves-
tigators applied the same technology to manipulate
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models. As with miR therapeutics, lncRNA manip-
ulation by antisense oligonucleotides or mimics may
become a valid therapeutic tool once hurdles con-
cerning delivery, speciﬁcity, tolerability of oligonu-
cleotides, and duration of action are overcome (13).
Second, the identiﬁcation of thousands of endo-
thelial lncRNAs with hypoxia-dependent dysregula-
tion offers a multitude of targets for therapeutic
angiogenesis, although their characterization will
require vast amounts of manpower, time, and
funding. Improving open-source tools available to
bioinformaticians and experimental biologists to
annotate and predict lncRNAs function is then
mandatory. At present, this study’s data repository
enables the ﬁeld to functionally characterize count-
less additional hypoxia-sensitive lncRNAs. Finally,
despite enthusiasm about the human EHT model as a
new pre-clinical testing modality, it remains to be
determined to what extent the EHT system truly re-
capitulates the adult human myocardium and which
aspect in the translational axis of disease modeling,target validation, molecule selection, and/or toxicity
testing will be accelerated by this pre-clinical model
system.
Notwithstanding these as yet unanswered ques-
tions, the present study delivers new targets for
therapeutic angiogenesis and is in support of the
premise that the noncoding genome may well harbor
many secrets amenable to therapeutic intervention
for various processes in severe heart disease. The
unlocking of new targets in the ill-explored domain
of the noncoding genome bears similarities to the
discovery of mythological Naiades in our search of
new freshwater springs that sprout new life and
energy to the dry and barren wastelands of the failing
myocardium.
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